 |
|
Contributed Poster Presentations – Session I |
|
ALLERGY/EYE DISORDERS |
|
|
CARDIOVASCULAR DISEASES/DISORDERS |
|
|
DIABETES |
|
|
GASTROINTESTINAL DISEASES/DISORDERS |
|
|
MENTAL HEALTH |
|
|
URINARY/KIDNEY DISEASES OR DISORDERS |
|
|
WOMEN’S & MEN’S HEALTH |
|
|
HEALTH CARE POLICY |
|
ALLERGY/EYE DISORDERS |
| |
Allergy – Cost Studies |
| PAE1 |
CHRONIC ALLERGIC RHINITIS, ECONOMICS IMPACT: FRENCH SITUATION
Myon E, Taïeb C, Pharmaco Economics & Quality of Life Department, Boulogne
Billancourt, France |
| PAE2 |
THE
BURDEN OF ALLERGIC CONJUNCTIVITIS IN THE UK: FINDINGS FROM A
RETROSPECTIVE REVIEW OF THE GPRD DATABASE 1990-2000
Smith AF1, Martinez C2, Rubino A2, Bron AJ3, Pitt AD4, 1Alcon Laboratories
Ltd and Nuffield Laboratory of Ophthalmology, University of Oxford, Hemel
Hempstead, Hertfordshire, United Kingdom; 2General Practice Research
Database, London, London, United Kingdom; 3Nuffield Laboratory of
Ophthalmology, University of Oxford, Oxford, Oxfordshire, United Kingdom;
4University of Oxford, Oxford, Oxfordshire, United Kingdom |
| PAE3 |
THE ECONOMIC AND QUALITY OF LIFE IMPACT OF SEASONAL ALLERGIC
CONJUNCTIVITIS IN OXFORDSHIRE, ENGLAND
Smith AF, Alcon Laboratories Ltd and Nuffield Laboratory of Ophthalmology,
University of Oxford, Hemel Hempstead, Hertfordshire, United Kingdom |
| |
Allergy – Quality of Life Studies |
| PAE4 |
CONSTRUCT VALIDITY AND RELIABILITY OF THE EYE ALLERGY PATIENT IMPACT
QUESTIONNAIRE (EAPIQ)
Alexander M1, Berger W2, Buchholz P3, Walt J4, Burk C5, Lee J4, Abetz L6,
Arbuckle R6, 1Niagara Falls Clinical Research, Niagara Falls, Ontario,
Canada; 2Southern California Resarch, Mission Viejo, CA, USA; 3Allergan,
Ettlingen, Germany; 4Allergan, Irvine, CA, USA; 5CTBurk, Inc, Laguna Beach,
CA, USA; 6Mapi Values, Bollington, Cheshire, United Kingdom |
| |
|
| |
Eye Diseases/Disorders – Clinical Outcomes Studies |
| PAE5 |
PREVALENCE OF LOW VISION AND
BLINDNESS IN FRANCE
Brézin A1, Lafuma A2, Fagnani F3, Mesbah M4, Berdeaux G5, 1Hopital COCHIN,
Paris, France; 2Cemka, Bourg-La-Reine, France; 3CEMKA, Bourg la Reine,
France; 4Université de Bretagne-Sud, Vannes, France; 5Alcon, Rueil-Malmaison,
France |
| PAE6 |
PREVALENCE AND BURDEN OF
BLINDNESS AND LOW VISION IN SUBJECTS LIVING IN INSTITUTIONS: A
NATION-WIDE SURVEY
Brézin A1, Lafuma A2, Fagnani F3, Mesbah M4, Berdeaux G5, 1Hopital COCHIN,
Paris, France; 2Cemka, Bourg-La-Reine, France; 3CEMKA, Bourg la Reine,
France; 4Université de Bretagne-Sud, Vannes, France; 5Alcon, Rueil-Malmaison,
France |
| PAE19 |
PREVALENCE AND BURDEN OF BLINDNESS, LOW VISION AND VISUAL IMPAIRMENT
IN THE COMMUNITY: A NATION-WIDE SURVEY
Brézin A1, Lafuma A2, Fagnani FV, Mesbah M4, Berdeaux G5, 1Hopital COCHIN,
Paris, France; 2Cemka, Bourg-La-Reine, France; 3CEMKA, Bourg la Reine,
France; 4Université de Bretagne-Sud, VANNES, France; 5Alcon, Rueil-Malmaison,
France |
| PAE7 |
VISION IMPAIRMENT AS AN INDEPENDENT RISK FACTOR OF INSTITUTIONALIZATION
Brézin A1, Lafuma A2, Fagnani F3, Mesbah M4, Berdeaux G5, 1Hopital COCHIN,
Paris, France; 2Cemka, Bourg-La-Reine, France; 3CEMKA, Bourg la Reine,
France; 4Université de Bretagne-Sud, Vannes, France; 5Alcon, Rueil-Malmaison,
France |
| PAE8 |
SCORING OF VISUAL FIELD MEASURED THROUGH HUMPHREY PERIMETRY: PRINCIPAL
COMPONENT VARIMAX ROTATION FOLLOWED BY CLUSTERING ANALYSIS
Nordmann J1, Mesbah M2, Berdeaux G3, 1Quinze-Vingts Centre Hospitalier
National d'Ophtalmologie, Paris, France; 2Université de Bretagne-Sud, Vannes,
France; 3Alcon, Rueil-Malmaison, France |
| |
|
| |
Eye Disorders – Cost Studies |
| PAE9 |
COST AND EFFECTIVENESS OF BRINZOLAMIDE VERSUS DORZOLAMIDE IN THE
TREATMENT OF GLAUCOMA: AN ANALYSIS CONDUCTED USING THE UNITED-KINGDOM
GENERAL PRACTITIONER RESEARCH DATABASE
Lafuma A1, Voinet C1, Berdeaux G2, 1Cemka, Bourg-La-Reine, France; 2Alcon,
Rueil-Malmaison, France |
| PAE10 |
COMPARISON OF THE CLINICAL
EFFICACY AND COST-EFFECTIVENESS OF LUMIGAN
AND XALATAN IN THE TREATMENT OF GLAUCOMA
Roberts G1, Buchholz P2, Holmstrom S3, Finck K3, Gillard S4, Warner J4,
Teale C1, 1Allergan Ltd, Buckinghamshire, United Kingdom; 2Allergan,
Ettlingen, Germany; 3Allergan, Mougins, France; 4ABACUS International,
Oxfordshire, United Kingdom |
| PAE11 |
ECONOMIC EVALUATION OF LATANOPROST AS FIRST LINE GLAUCOMA THERAPY IN 6
EUROPEAN COUNTRIES
Aballéa S1, Martin M2, Bernard LV, Althin R4, 1Innovus Research UK, High
Wycombe, United Kingdom; 2Innovus Research, High Wycombe, United Kingdom;
3Innovus Research Inc, Burlington, ON, Canada; 4Pfizer, High Wycombe, United
Kingdom |
| PAE12 |
TREATMENT DURATION AS
A COST DRIVER OF GLAUCOMA CARE: A LIFE-LONG SOCIETAL PERSPECTIVE IN
FRANCE, GERMANY AND THE NETHERLAND
Lafuma A1, Voinet C1, Berdeaux G2, 1Cemka, Bourg-La-Reine, France; 2Alcon,
Rueil-Malmaison, France |
| PAE13 |
COST-EFFECTIVENESS ANALYSIS
OF TIMOLOL LATANOPROST AND TRAVOPROST IN 3
EUROPEAN COUNTRIES: THE UK, GERMANY AND FRANCE
Lilliu H1, Ligier M1, Le Pen C1, Berdeaux G2, 1Clp-santé, Paris, France;
2Alcon, Rueil-Malmaison, France |
| PAE14 |
COST-EFFECTIVENESS
ANALYSIS OF PMMA, SILICONE, AND ACRYLIC
INTRA-OCULAR LENSES IN CATARACT THERAPY IN FOUR EUROPEAN COUNTRIES
Smith AF1, Lafuma A2, Berto P3, Magaz S4, Berdeaux G5, Auffarth G6, Brézin
A7, Caporossi A8, Mendicute J9, Brueggenjuergen B10, 1Alcon Laboratories Ltd
and Nuffield Laboratory of Ophthalmology, University of Oxford, Hemel
Hempstead, Hertfordshire, United Kingdom; 2CEMKA, Bourg la Reine, France;
3PBE Consulting, Verona, Italy; 4Health Outcomes Policy and Economics,
Barcelona, Spain; 5Alcon, Rueil-Malmaison, France;
6Ruprecht-Karls-Universitat, Heidelberg, Heidelberg, Germany; 7Hopital
Cochin, Paris, France; 8Universita di Siena, Sienna, Italy; 9Hospital
Donostia, Donostia San Sebastain, San Sebastain, Spain; 10Alphacare, Celle,
Germany |
| PAE15 |
A MULTI-CENTER RETROSPECTIVE STUDY OF RESOURCE UTILIZATION AND COSTS
ASSOCIATED WITH GLAUCOMA MANAGEMENT IN FRANCE AND SWEDEN
Orme M1, Curry A1, Buchholz P2, Walt J3, Groleau D4, Holmstrom S5,
1Quintiles UK Ltd, Berkshire, United Kingdom; 2Allergan, Ettlingen, Germany;
3Allergan, Irvine, CA, USA; 4Allergan UK Ltd, Oxford, United Kingdom;
5Allergan, Mougins, France |
| |
|
| |
Eye Disorders - Quality of Life Studies |
| PAE16 |
PSYCHOMETRIC VALIDATION OF THE NEI-VFQ 25 FRENCH VERSION IN A
POPULATION OF PATIENTS TREATED FOR OCULAR HYPERTENSION AND GLAUCOMA
Nordmann J1, Sullivan K2, Viala M2, Arnould B3, Berdeaux G4, 1Quinze-Vingts
Centre Hospitalier National d'Ophtalmologie, Paris, France; 2Mapi Values,
Lyon, Rhone, France; 3Mapi Values, Lyon, France; 4Alcon, Rueil-Malmaison,
France |
| PAE17 |
ASSESSING THE VALUE OF LASER
IN SITU KERATOMILEUSIS (LASIK) BY PATIENT
REPORTED OUTCOMES
Kang HY1, Cho WH1, Lee JH2, Lee JM2, Park KH2, 1Yonsei University, Seoul,
South Korea; 2Chungdam Balgeunsesang Eye Clinic, Seoul, South Korea |
| PAE18 |
IMPROVEMENT IN VISION TARGETED QUALITY OF LIFE (QOL) AFTER CATARACT
SURGERY WITH IMPLANTATION OF ACRYSOF® NATURAL INTRAOCULAR LENS (IOL)
Venkataraman K, Barnes R, Alcon Labs, Fort Worth, TX, USA |
| |
|
| |
|
|
CARDIOVASCULAR DISEASES/DISORDERS |
| |
Cardiovascular Disease – Clinical Outcomes Studies |
| PCV1 |
PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION,
ELEVATED TROPONIN T LEVELS AND DIABETES MELLITUS. OUTCOME AT THREE MONTHS
Salvador A, Sevilla B, Roldán I, Baello P, Salim M,
Peláez A, Vaquerizo B,
Aguar P, Tuzón MT, Mora V, Romero JE, Dr. Peset Hospital, Valencia, Spain |
| PCV2 |
NEW TECHNOLOGIES IN THE US MEDICARE: AN EXAMINATION OF STENT ADOPTION
Linde-Zwirble WT1, Ball D2, Copper LM2, 1Health Process Management,
Doylestown, PA, USA; 2Eli Lilly and Co, Indianapolis, IN, USA |
| PCV3 |
EFFECTIVENESS OF LIPID-LOWERING THERAPY IN PRIMARY CARE IN FRANCE
Van Ganse E1, Moulin P2, Bertrand M3, Souchet T4, Pietri G1, Yin D5, de
Pouvourville G6, 1Lyon Sud Hospital, Lyon, France; 2Louis Pradel Hospital,
Lyon, France; 3Lille University Hospital, Lambersart, France; 4Merck Sharp &
Dohme - Chibret, Paris, France; 5Merck & Co, Whitehouse, NJ, USA; 6INSERM U
537, Le Kremlin-Bicêtre, France |
| PCV4 |
PREVENTION OF DEEP-VEIN THROMBOSIS AFTER TOTAL KNEE ARTHROPLASTY IN
ASIAN PATIENTS: COMPARISON OF PROPHYLAXIS WITH LOW MOLECULAR WEIGHT HEPARIN
AND INDOMETHACIN
Wang CJ, Chang Gung Memorial Hospital At Kaosiung, Taiwan |
| PCV5 |
OUTCOME AND PROGNOSTIC VALUE OF TROPONIN T IN PATIENTS WITH UNSTABLE
ANGINA OR NON-Q-WAVE MYOCARDIAL INFARCTION
Peláez A, Roldán I, Sevilla B, Baello P, Salim M, Tuzón MT, Mora V,
Vaquerizo B, Martínez-Diago V, Aguar P, Orriach MD, Salvador A, Dr. Peset
Hospital, Valencia, Valencia, Spain |
| PCV6 |
ASSESSMENT OF THE QUALITY OF
DRUG TREATMENT IN ESSENTIAL HYPERTENSION IN SLOVAK REPUBLIC
Szalayova A, Dubrava M, Kriska M, Comenius University, Bratislava, Slovak
Republic |
| PCV7 |
MITRAL REPAIR CAN BE SAFELY PERFORMED IN CASES OF INCREASED COMPLEXITY
Sonnad SS1, Badhwar V2, Smolens IA2, Bolling SF2, 1University of
Pennsylvania, Philadelphia, PA, USA; 2University of Michigan, Ann Arbor, MI,
USA |
| PCV8 |
CHOICE OF FIRST-LINE
TREATMENT FOR HYPERTENSION IN THE UK: DOES CURRENT PRIMARY CARE PRACTICE
REFLECT BRITISH GUIDELINES?
Duerden MG1, Allinson MD1, Thompson M2, 1Keele University, Keele,
Staffordshire, United Kingdom; 2IMS Health, Pinner, Middlesex, United
Kingdom |
| |
|
| PCV9 |
THE USE OF SHORT MESSAGES TO THE PATIENT'S MOBILE PHONE AS HEALTH CARE
TOOL IN HYPERTENSION: THE HTA-ALERT STUDY AND THE INFONET PROGRAM
Figueras M1, De la Figuera M2, Márquez E3, Ruilope LM4, Segura J4,
Ylla-Català A1, Galera J1, Balañá M1, Naval J5, The HTA-Alert Study Group
16, The INFONET Study Group 17, 1Novartis Farmacéutica, S.A, Barcelona,
Spain; 2ABS La Mina. Grupo Cumplimiento Sehlelha, Sant Adrià del Besòs.
Barcelona, Spain; 3C.S. La Orden. Grupo Cumplimiento Sehlelha, Huelva,
Spain; 4Hospital 12 de Octubre. Sehlelha, Madrid, Spain; 5Infociencia, S.L,
Barcelona, Spain; 6The HTA-Alert Study Group, Barcelona, Spain; 7The INFONET
Study Group, Barcelona, Spain |
| PCV10 |
IMPROVED COMPLIANCE AND PERSISTENCE WITH ATORVASTATINE THROUGH A
PHARMACY-BASED INTERVENTION.
de Klerk E, AARDEX Ltd, Maastricht, The Netherlands |
| PCV11 |
PREDICTIVE VALUE OF TROPONIN T LEVELS FOR HEART FAILURE AFTER UNSTABLE
ANGINA OR NON ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION
Tuzón MT, Baello P, Sevilla B, Roldán I, Peláez A, Vaquerizo B, Aguar P,
Salim M, Montagud V, Almela M, Rincón de Arellano A, Salvador A, Dr. Peset
Hospital, Valencia, Valencia, Spain |
| PCV12 |
EFFECT OF EPROSARTAN ON PULSE PRESSURE PREDICTIVE FACTORS OF RESPONSE
de la Sierra A1, Arcos E2, Muñoz A3, Relats J3, López JS2, 1Hypertension
Unit. Hospital Clínic (Barcelona), Barcelona, Spain; 2Pharma-Consult,
Barcelona, Spain; 3Solvay Pharma, Barcelona, Spain |
| PCV13 |
A SYSTEMATIC REVIEW AND
META-ANALYSIS OF STUDIES COMPARING READMISSION RATES AND MORTALITY IN
PATIENTS WITH HEART FAILURE
Gwadry-Sridhar F, Flintoft V, McMaster University, London, ON, Canada
PCV14 EFFECTIVENESS OF SELF-MEASUREMENT OF BLOOD PRESSURE IN HYPERTENSIVE
PATIENTS. DIOAMPA STUDY
Figueras M1, Dalfó A2, Capillas R3, Guash MM4, Ylla-Català A1, Gallardo I1,
Balañá M1, Cobos A5, Vidal JM4, 1Novartis Farmaceutica S.A, Barcelona,
Spain; 2Equipo de Atención Primária Gòtic, Barcelona, Spain; 3ABS Sant Josep,
L'Hospitalet, Barcelona, Spain; 4ABS-"D Universitat, Barcelona, Spain;
5Redes, S.L, Barcelona, Spain |
| PCV14 |
EFFECTIVENESS OF
SELF-MEASUREMENT OF BLOOD PRESSURE IN HYPERTENSIVE PATIENTS.DIOAMPA
STUDY
Figueras M1, Dalfó A2, Capillas R3,
Guash MM4, Ylla-Català A1, Gallardo I1, Balañá M1, Cobos A5, Vidal JM4,
1Novartis Farmaceutica S.A,Barcelona,Spain; 2Equipo de Atención Primária
Gòtic,Barcelona, Spain; 3ABS Sant Josep, L'Hospitalet, Barcelona, Spain;
4ABS-"D Universitat, Barcelona, Spain; 5Redes, S.L,Barcelona, Spain |
| PCV15 |
LOW GOAL ATTAINMENT IN
COMMON DAILY PRACTICE AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA IN THE
NETHERLANDS: THE REALITY-PHARMO STUDY
Goettsch WG1, Yin DD2, Alemao E2, Klungel OH3, Stalenhoef AF4, Herings RMC1,
1PHARMO Institute, Utrecht, The Netherlands; 2Merck & Co., Inc, Whitehouse
Station, NJ, USA; 3Utrecht University, Utrecht, The Netherlands; 4University
Medical Centre, Nijmegen, The Netherlands |
| |
|
| |
Cardiovascular Disease – Cost Studies |
| PCV16 |
EFFECTIVENESS AND
COST-EFFECTIVENESS OF THE AMBULATORY BLOOD PRESSURE MONITORING (ABPM) IN THE DIAGNOSTIC OF HYPERTENSION
Rebollo P1, Marin R2, Ortega F1, Valdés C1, Ortega T3, Alvarez-Grande J2,
1Hospital Universitario Central de Asturias and Institute "Reina Sofía" for
Nephrological Research, Oviedo, Asturias, Spain; 2Hospital Universitario
Central de Asturias, Oviedo, Asturias, Spain; 3Hospital Central de Asturias
and Institute "Reina Sofia" for Nephrological Research, Oviedo, Asturias,
Spain |
| PCV17 |
COST-EFFECTIVENESS ANALYSIS
OF DALTEPARIN IN PROLONGED PROPHYLAXIS
AGAINST DEEP VEIN THROMBOSIS AFTER HIP ARTHROPLASTY
Segú JL1, Soto J2, 1CAP la Barceloneta, Barcelona, Spain; 2Pfizer, S.A,
Alcobendas, Madrid, Spain |
| PCV18 |
HEALTH SYSTEM COSTS OF OUT-OF-HOSPITAL CARDIAC ARREST IN RELATION TO
TIME TO SHOCK
Van Alem AP, Dijkgraaf MGW, Koster RW, Academic Medical Center / University
of Amsterdam, Amsterdam, The Netherlands |
| PCV19 |
A PROBABILISTIC MODEL TO
ASSESS THE COST-EFFECTIVENESS OF A NEW STATIN
(ROSUVASTATIN) IN THE UK
Palmer S1, Brady AJ2, Ratcliffe A3, 1University of York, York, North
Yorkshire, United Kingdom; 2Glasgow Royal Infirmary, Glasgow, United
Kingdom; 3AstraZeneca UK Ltd, Luton, Bedfordshire, United Kingdom |
| PCV20 |
ECONOMIC MODELLING OF ANTIPLATELET THERAPY IN THE PREVENTION OF
RECURRENT STROKE
Beard S1, Gaffney L1, Bamber L2, 1RTI Health Solutions, Manchester, United
Kingdom; 2Boehringer Ingelheim Limited, Bracknell, United Kingdom
PCV21 THE COST OF STROKE IN SWEDEN – AN INCIDENCE ESTIMATE
Ghatnekar O1, Persson U1, Glader EL2, Terént A3, 1IHE, Lund, Sweden; 2Umea
University Hospital, Umea, Norrland, Sweden; 3Uppsala University Hospital,
Uppsala, Sweden |
| |
|
| PCV21 |
THE COST OF
STROKE IN SWEDEN – AN INCIDENCE ESTIMATE
Ghatnekar O1, Persson U1, Glader EL2, Terént A3,
1IHE,Lund,Sweden; 2Umea University Hospital,Umea, Norrland,Sweden;
3Uppsala University Hospital,Uppsala, Sweden |
| PCV22 |
ECONOMIC EVALUATION OF FONDAPARINUX COMPARED TO ENOXAPARIN IN VENOUS
THROMBOEMBOLISM PREVENTION FOLLOWING HIP FRACTURE SURGERY
Gordois A1, Minjoulat-Rey MC2, Carita P2, Gabriel S2, Posnett J2,
1University of York, York, United Kingdom; 2Sanofi Synthelabo Recherche,
Bagneux, France |
| PCV23 |
ECONOMIC IMPACT OF CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY
SYNDROMES WITHOUT ST- SEGMENT ELEVATION (ACS) UNDERGOING PERCUTANEOUS
CORONARY INTERVENTIONS (PCI): A EUROPEAN OVERVIEW
Spiesser J1, Carita P1, Annemans L2, Lüscher T3, Schwarz B4, Gabriel S5,
1Sanofi-Synthelabo Recherche, Bagneux, France; 2Ghent University, HEDM,
Meise, Belgium; 3University Hospital Zurich, Zurich, Switzerland;
4University Vienna, Vienna, Austria; 5Sanofi Synthelabo, Bagneux, France |
| PCV24 |
THE MAHLER STUDY:
DIFFERENCES IN RESOURCE USE FOR THE MANAGEMENT OF CHRONIC HEART FAILURE
ACROSS 6 EUROPEAN COUNTRIES
Lilliu H1, Le Pen C1, Lapuerta P2, Gonzalez-Juanatey J3, Van Veldhuisen D4,
Erdmann E5, Poole-Wilson P6, Tavazzi L7, Hermans N8, Priol G1, Komajda M9,
1Clp-santé, Paris, France; 2Bristol-Myers Squibb, Princeton, NJ, USA;
3Hospital Clinico Universitario, Santiago de Compostela, Spain; 4University
Hospital, Groningen, The Netherlands; 5University of Köln, Köln, Germany;
6National Heart and Lung Institute, London, United Kingdom; 7IRCCS
Policlinico S. Matteo, Pavia, Italy; 8Bristol-Myers Squibb, Waterloo,
Belgium; 9Centre Hospitalier Pitié-Salpetrière, Paris, France |
| PCV25 |
THE COST AND THE MANAGEMENT OF THE ACUTE PHASE OF MYOCARDIAL
INFARCTION AND STROKE IN HUNGARY
Borsos K1, Nagy J2, Belicza E2, Blaskó G1, Spiesser J3, 1Sanofi-Synthelabo
Hungary, Budapest, Hungary; 2Egészségügy-kutató Intézet, Budapest, Hungary;
3Sanofi-Synthelabo Recherche, Bagneux, France |
| |
|
| PCV26 |
COST-EFFECTIVENESS OF
EXTENDING PROPHYLAXIS WITH FONDAPARINUX IN
PREVENTING VENOUS THROMBOEMBOLISM FOLLOWING HIP FRACTURE SURGERY
van HOUT BA1, Minjoulat-Rey MC2, Quinlan D3, Theeuwes A4, Gabriel S2,
1University of Utrecht, Utrecht, The Netherlands; 2Sanofi Synthelabo
Recherche, Bagneux, France; 3King's College Hospital, London, United
Kingdom; 4Organon, Oos, The Netherlands |
| PCV27 |
COST-EFFECTIVENESS ANALYSIS
OF ANTITHROMBOTIC TREATMENT WITH
CLOPIDOGREL IN PATIENTS WITH MYOCARDIAL INFARCTION, STROKE, AND PERIPHERAL
ARTERIAL DISEASE IN THE NETHERLANDS
van Hout BA1, Tangelder MJD2, Bervoets P3, Gabriel S4, 1Pharmerit, Capelle
aan de IJssel, The Netherlands; 2Sanofi-Synthelabo, Maassluis, The
Netherlands; 3Bristol-Myers Squibb, Woerden, The Netherlands; 4Sanofi
Synthelabo, Bagneux, France |
| PCV28 |
ECONOMIC EVALUATION AND
SURVIVAL ANALYSIS OF IMMUNO-ADSORPTION IN
PATIENTS WITH DILATED CARDIOMYOPATHY
Hessel FP1, Wegner C2, Mueller J3, Wasem J1, 1University Duisburg-Essen,
Essen, Germany; 2University of Greifswald, Greifswald, Germany; 3German
Heart Centre Berlin, Berlin, Germany |
| PCV29 |
USE OF RESOURCES AND COST
IMPLICATIONS OF STROKE PROPHYLAXIS WITH WARFARIN FOR PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
Abdelhafiz AH, Wheeldon N, Sheffield University, Sheffield, United Kingdom |
| PCV30 |
COST-EFFECTIVENESS ANALYSIS
OF ROSUVASTATIN IN GREEK PATIENTS WITH
HYPERLIPIDAEMIA
Papageorgiou M1, Karokis A1, Plumb J2, Ratcliffe A2, Southworth H3,
1AstraZeneca SA, Athens, Greece; 2AstraZeneca UK Ltd, Luton, Bedfordshire,
United Kingdom; 3AstraZeneca R&D, Macclesfield, Cheshire, United Kingdom |
| PCV31 |
ECONOMIC EVALUATION OF CLOPIDOGREL IN SECONDARY PREVENTION OF
ATHEROTHROMBOTIC EVENTS IN HUNGARY
Borsos K1, Nagy J2, Belicza E2, Spiesser J3, Gabriel S4, Blasko G1,
1Sanofi-Synthelabo Hungary, Budapest, Hungary; 2Egészségügy-kutató Intézet,
Budapest, Hungary; 3Sanofi-Synthelabo Recherche, Bagneux, France; 4Sanofi
Synthelabo, Bagneux, France |
| |
|
| PCV32 |
COSTS OF HOSPITALIZATION IN
DEPARTMENT OF CARDIOLOGY FOR PATIENTS WITH SYSTOLIC HEART FAILURE IN
FRANCE
Brunot A1, Lenne X1, Dervaux B1, Vincent C2, Degroote P3, 1CRESGE -
Université Catholique de Lille, Lille, France; 2Orion Pharma France,
Levallois Perret, France; 3Centre Hospito-Universitaire de Lille, Lille,
France |
| PCV33 |
THE COST-EFFECTIVENESS OF TARKA IN THE TREATMENT OF HEART FAILURE
AFTER MYOCARDIAL INFARCTION IN THE US HEALTH CARE SETTING
Nuijten M1, Wittenberg W2, Engelfriet P3, Engelfriet P3, 1MEDTAP
International, Jisp, The Netherlands; 2ABBOTT GmbH &Co KG, Ludwigshafen,
Germany; 3MEDTAP International Inc, Utrecht, The Netherlands |
| PCV34 |
COST-EFFECTIVENESS OF
FRACTIONAL FLOW RESERVE TESTING TO GUIDE PERCUTANEOUS CORONARY INTERVENTION IN THE DRUG-ELUTING STENT ERA: A DECISION
ANALYSIS
Siebert U1, Greenberg D1, Kuntz KM2, Cohen DJ1, 1Harvard University, Boston,
MA, USA; 2Harvard School of Public Health, Boston, MA, USA |
| PCV35 |
BURDEN OF
HYPERCHOLESTEROLEMIA IN GERMANY
Upmeier H1, Mueller-Nordhorn J1, Englert H1, Sonntag F2, Voeller H3,
Wegscheider K4, Windler E4, Meyer-Sabellek W5, Katus HA6, Willich SN1,
1Institute of Social Medicine, Epidemiology and Health Economics, Charité
Hospital, Humboldt University of Berlin, Berlin, Germany; 2Cardiologist,
Henstedt-Ulzburg, Germany; 3Rehabilitation Center for Cardiovascular
Diseases, Rüdersdorf, Germany; 4University of Hamburg, Hamburg, Germany;
5AstraZeneca GmbH, Wedel, Germany; 6University of Heidelberg, Heidelberg,
Germany |
| PCV36 |
COST-EFFECTIVENESS OF EARLY THROMBOLYSIS FOR THE TREATMENT OF ACUTE
MYOCARDIAL INFARCTION: A SYSTEMATIC REVIEW OF THE LITERATURE
Boland A, Haycox A, Mujita Mota R, Dundar Y, Bagust A, Dickson R, Walley T,
University of Liverpool, Liverpool, United Kingdom |
| PCV37 |
THE ADDITIONAL TREATMENT OF
PATIENTS WITH CHRONIC HEART FAILURE WITH METOPROLOL CR/XL WILL LEAD TO COST SAVINGS IN THE GERMAN HEALTH CARE SYSTEM
Pirk O1, Schoeffski O2, 1Fricke & Pirk GmbH, Nuremberg, Germany; 2University
Erlangen-Nuremberg, Nuremberg, Germany |
| |
|
| PCV38 |
COST-EFFECTIVENESS OF
TREATING BY SIMVASTATIN 40 MG/DAY HIGH VASCULAR
RISK PATIENTS: AN ECONOMIC EVALUATION BASED ON THE HEART PROTECTION STUDY
Fagnani F1, Lafuma A1, Souchet T2, 1CEMKA, Bourg la Reine, France; 2Merck
Sharp & Dohme - Chibret, Paris, France |
| PCV39 |
ECONOMIC EVALUATION OF THE MEDENOX (PROPHYLAXIS IN MEDICAL PATIENTS
WITH ENOXAPARIN) TRIAL FROM THE PERSPECTIVE OF HOSPITALS IN GERMANY: RESULTS
OF A SUBGROUP ANALYSIS
Schädlich PK1, Kentsch M2, Weber M3, Kämmerer W4, Nadipelli V5, Huppertz E6,
Brecht JG1, 1InForMed GmbH - Outcomes Research & Health Economics,
Ingolstadt, Bavaria, Germany; 2Clinics of Itzehoe, Itzehoe, SH, Germany;
3Clinics of the City of Cologne, Cologne-Merheim, NRW, Germany;
4Dr-Horst-Schmidt-Clinics, Wiesbaden, Hesse, Germany; 5Aventis
Pharmaceuticals, Bridgewater, NJ, USA; 6Aventis Pharma Deutschland, Bad
Soden am Taunus, Hesse, Germany |
| PCV40 |
ASSESSMENT OF THE COST OF
CARDIOVASCULAR DEATH
Lamotte M1, Caekelbergh K2, Annemans L3, De Keyser P4, 1Health Economics
Disease Management (HEDM), Meise, Belgium; 2HEDM, Meise, Belgium; 3Ghent
University, HEDM, Meise, NA, Belgium; 4Solvay Pharma, Brussels, NA, Belgium |
| PCV41 |
A COST ANALYSIS IN PATIENTS WITH ACUTE CORONARY SYNDROMES USING CLOPIDOGREL IN ADDITION TO ASPIRIN IN A HONG KONG PUBLIC HOSPITAL
Lee VW1, Chan WK2, Lau WH1, Lee KK1, 1The Chinese University of Hong Kong, Shatin, Hong Kong, China; 2United Christian Hospital, Kwun Tong, Hong Kong,
China |
| PCV42 |
ECONOMIC ANALYSIS OF THE USE
OF CONTRAST MEDIA DURING PERCUTANEOUS
CORONARY INTERVENTION (PCI) IN FRANCE AND SPAIN
Danchin N1, Macaya C2, Tao WY3, 1HEGP Hospital, Paris, France; 2Hospital
University San Carlos, Madrid, Spain; 3The Lewin Group, Hoofddorp, The
Netherlands |
| PCV43 |
AN EVALUATION OF THE COSTS
ASSOCIATED WITH ACUTE MI TREATMENT IN AND OUT OF HOSPITALS IN GREECE
Maniadakis N1, Fragoulakis B2, Liapis M3, Hatzikou M4, 1University of Patras,
Patras, Greece; 2University Hospital Patras, Patras, Greece; 3Boehringer
Ingelheim, Athens, Greece; 4Boehringer Ingelheim, Athens, Greece |
| |
|
| PCV44 |
PHARMACOECONOMIC EVALUATION OF VASOTEC® IN HYPERTENSIVE PATIENTS WITH
CONGESTIVE HEART FAILURE : AN UPDATE OF THE RETROSPECTIVE CANADIAN ANALYSIS
BASED ON THE STUDIES OF LEFT VENTRICULAR DYSFUNCTION (SOLVD)
Desjardins B1, Marceau C1, Cook JR2, Glick HA3, 1Merck Frosst Canada Ltd,
Kirkland, QC, Canada; 2Merck and Co, Blue Bell, PA, USA; 3University of
Pennsylvania, Philadelphia, PA, USA |
| PCV45 |
LONG-TERM COST-EFFECTIVENESS
OF PRIMARY ANGIOPLASTY COMPARED TO FIBRINOLYSIS IN ACUTE MYOCARDIAL INFARCTION
Sridhar K, Mahon JL, University of Western Ontario, London, ON, Canada |
| PCV46 |
SWITCHING PATIENTS TO ROSUVASTATIN FROM ATORVASTATIN OR OTHER STATINS
IS COST-EFFECTIVE: PHARMACOECONOMIC ANALYSIS OF MERCURY I
James M1, Brown J2, Schuster H3, 1AstraZeneca UK Ltd, Macclesfield,
Cheshire, United Kingdom; 2AstraZeneca, Macclesfield, Cheshire, United
Kingdom; 3INFOGEN Medizinische Genetik GmbH, Berlin, Germany |
| PCV47 |
A COST-EFFECTIVENESS
ANALYSIS OF TAXUSTM DRUG-ELUTING STENT IN THE UK
Wenk-Lang A1, Knight C2, 1Boston Scientific International, La Garenne
Colombes, France; 2Heron Evidence Development Ltd, Letchworth, United
Kingdom |
| PCV48 |
LONG-TERM COST-EFFECTIVENESS
OF INVASIVE STRATEGY IN PATIENT WITH UNSTABLE CORONARY ARTERY DISEASE -
RESULTS FROM THE FRISC-II TRIAL
Levin LÅ1, Janzon M2, Swahn E2, 1Center for Medical Technology Assessment
CMT, Linköping, Sweden; 2Linköping Universitet, Linköping, Sweden |
| PCV49 |
COST-EFFECTIVENESS ANALYSIS
OF CITICOLINE VS CONVENTIONAL TREATMENT IN
STROKE PATIENTS
Casado A1, Lozano R2, Ibarz R1, Herdman M1, 13D Health Research, Barcelona,
Spain; 2Grupo Ferrer S.A, Barcelona, Spain |
| PCV50 |
COSTS OF THE DIAGNOSIS OF
RENAL ARTERY STENOSIS
van Helvoort-Postulart D1, Dirksen CD1, van Engelshoven JM1, Hunink MG2,
1University Hospital Maastricht, Maastricht, Limburg, The Netherlands;
2Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands |
| PCV51 |
IRBESARTAN IS COST-SAVING COMPARED TO AMLODIPINE
AND STANDARD BLOOD PRESSURE TREATMENT IN PATIENTS WITH TYPE 2 DIABETES,
HYPERTENSION AND NEPHROPATHY IN HUNGARY
Palmer AJ1, Borsos K2, Roze S3, Annemans L4, Lamotte M5, Rodby R6, Valentine
WJ3, 1CORE Center for Outcomes Research, Basel, BS, Switzerland;
2Sanofi-Synthelabo Hungary, Budapest, Hungary; 3CORE Center for Outcomes
Research, Basel, Switzerland; 4University of Ghent, Meise, Belgium; 5Ghent
University, Meise, Belgium;
6Rush Presbyterian/St. Luke's Medical Center, Chicago, IL, USA |
| |
|
| PCV52 |
ECONOMIC ANALYSIS OF THE USE
OF CLOPIDOGREL IN PATIENTS WITH ACUTE
CORONARY SYNDROME WITHOUT ST-SEGMENT ELEVATION (ACS) FROM THE RUSSIAN HEALTH
CARE SYSTEM PERSPECTIVE
Belousov YB1, Lazebnik LB1, Bykov AV2, Nguyen T3, Spiesser J4, 1Russian
State Medical University, Moscow, Russia; 2Russian Society for
Pharmacoeconomics Research, Moscow, Russia, Moscow, Russia;
3Sanofi-Synthelabo Groupe, Gentilly, France; 4Sanofi-Synthelabo Recherche,
Bagneux, France |
| PCV53 |
MANAGEMENT OF THE PRIMARY
CARE HYPERCHOLESTEROLEMIC PATIENTS THROUGH A
CLINICAL DECISION SUPPORT SYSTEM. OPTIMCARE STUDY REPORT
Gambus G1, Bassa A2, Del Val M2, Cobos A3, Torremade E1, Bergonon S3, Crespo
C4, Brosa M4, Munio S5, Espinosa C1, 1Novartis Farmacéutica S.A, Barcelona,
Spain; 2Vila Olimpica Primary Health Care Center, Barcelona, Spain; 3Rdes,
Barcelona, Spain; 4GOC Networking, Barcelona, Spain; 5Laboratorios Geminis
S.A, Barcelona, Spain |
| PCV54 |
ECONOMIC EVALUATION OF ROSUVASTATIN IN A NATURALISTIC SETTING
Jansen JP1, Goettsch WG2, van Loon J1, Herings RM2, 1Mapi Values, Houten,
The Netherlands; 2PHARMO Institute, Utrecht, The Netherlands |
| PCV55 |
"FAST-TRACKING" IN THE
CARDIAC INTENSIVE CARE UNIT: A TRIAL-BASED ECONOMIC EVALUATION OF THREE
SEDATION/ANALGESIA PROTOCOLS IN THE MANAGEMENT OF PATIENTS FOLLOWING
CARDIAC SURGERY
Long KH, Oliver Jr WC, Mc Murtry EK, Abel M, Nuttall G, Orszulak TA, Schaff
HV, Schroeder DR, Ereth MH, Mayo Clinic, Rochester, MN, USA |
| PCV56 |
ESTABLISHING THE COST-EFFECTIVENESS OF STATINS IN THE PRIMARY
PREVENTION OF CHD USING A QUASI MARKOV MODEL
Dewilde S, Davies A, Hutton J, MEDTAP International, London, United Kingdom |
| PCV57 |
COST EFFECTIVENESS OF
ANTIHYPERTENSIVE THERAPY IN DIABETIC PATIENTS IN ITALY
Mantovani LG1, Bustacchini S2, Ruffo P2, 1University of Milan, Milan, Italy;
2Pfizer Italia S.r.l, Rome, Italy |
|
PCV58 |
ECONOMIC IMPACT OF SELECTED FIXED-COMBINATION ANGIOTENSIN-CONVERTING
ENZYME INHIBITOR/CALCIUM CHANNEL BLOCKER ANTI-HYPERTENSIVES AMONG PATIENTS
WITH DIABETES
Joyce AT, Pedan A, Girase PS, Rucker MB, Ollendorf D, PharMetrics Inc,
Watertown, MA, USA |
| |
|
| PCV59 |
ECONOMIC EVALUATION OF LOSARTAN COMPARED WITH ATENOLOL IN THE
TREATMENT OF HYPERTENSION WITH LEFT VENTRICULAR HYPERTROPHY:
COST-MINIMIZATION ANALYSIS BASED ON LIFE STUDY
Chevreul K1, Durand-zaleski I2, Souchet T3, 1Robert Debré Hospital, Paris,
France; 2Henri Mondor Hospital, Créteil, France; 3Merck Sharp & Dohme -
Chibret, France, Paris, France |
| PCV60 |
INTRODUCTION OF ROSUVASTATIN WILL ENABLE MORE PATIENTS TO ACHIEVE
GUIDELINE LDL-C GOALS WITHIN A FIXED BUDGET IN THE UK
Ryan J1, Gilmour R2, Piercy J3, Saleh A4, Brown J5, 1Mapi Values,
Macclesfield, United Kingdom; 2Adelphi Medi Cine, London, United Kingdom;
3Adelphi Group, Macclesfield, Cheshire, United Kingdom; 4Mapi Values,
Macclesfield, Cheshire, United Kingdom; 5AstraZeneca, Macclesfield,
Cheshire, United Kingdom |
| PCV61 |
THE COST-EFFECTIVENESS OF
EXTENDED VENOUS THROMBOEMBOLISM PROPHYLAXIS
WITH ENOXAPARIN VERSUS SHORT-TERM PROPHYLAXIS AFTER ELECTIVE HIP REPLACEMENT
IN POLAND
Orlewska E, Medical University of Warsaw, Warsaw, Poland |
| PCV62 |
CLINICAL AND ECONOMIC
OUTCOMES OF FONDAPARINUX VS. ENOXAPARIN IN THE
PROPHYLAXIS OF VENOUS THROMBOEMBOLISM AFTER MAJOR ORTHOPAEDIC SURGERY IN
SPAIN
Slof J1, Magaz S1, Badia X2, 1Health Outcomes Policy & Economics, Barcelona,
Spain; 2Health Outcomes Research Europe Group, Barcelona, Spain |
| PCV63 |
COST-EFFECTIVENESS ANALYSIS
OF CLOPIDOGREL IN ACUTE CORONARY SYNDROMES
WITHOUT ST-SEGMENT ELEVATION IN THE NETHERLANDS
van Hout BA1, Tangelder MJD2, Bervoets P3, Gabriel S4, 1Pharmerit, Capelle
aan de IJssel, The Netherlands; 2Sanofi-Synthelabo, Maassluis, The
Netherlands; 3Bristol-Myers Squibb, Woerden, The Netherlands; 4Sanofi
Synthelabo, Bagneux, France |
| PCV64 |
COST-EFFECTIVENESS ANALYSIS
OF CORONARY REVASCULARISATION TECHNIQUES
AVAILABLE FOR THE TREATMENT OF ISCHAEMIC HEART DISEASE
Magaz S1, Badia X2, Annemans L3, Lamotte M4, 1Health Outcomes Policy And
Economics, Barcelona, Spain; 2Health Outcomes Research Europe Group,
Barcelona, Spain; 3Ghent University, HEDM, Meise, Belgium; 4Health Economics
Disease Management (HEDM), Meise, Belgium |
| |
|
| PCV65 |
EVALUATING THE ECONOMIC
VALUE OF SIROLIMUS-ELUTING STENT IN KOREA
Kang HY1, Park EC1, Park KD2, Park JE1, Lee HY1, 1Yonsei University, Seoul,
South Korea; 2Seoul National University, Seoul, South Korea |
| PCV66 |
ONE BILLION EURO FOR THE
TREATMENT WITH CSE-ANTAGONISTS IN GERMANY –
WHAT ARE THE RESULTS?
Pirk O1, Raming B2, Schoeffski O3, 1Fricke & Pirk GmbH, Nuremberg, Germany;
2AstraZeneca GmbH, Wedel, Germany; 3University Erlangen-Nuremberg,
Nuremberg, Germany |
| PCV67 |
AN ECONOMIC EVALUATION OF ALTEPLASE, RETEPLASE AND TENECTEPLASE IN
TREATMENT OF ACUTE MI IN GREECE
Maniadakis N1, Hatzikou M2, Kaitelidou D3, Spinthouri M4, Siskou O3,
Fragoulakis B5, Liappis T6, Liaropoulos L4, 1University of Patras, Patras,
Greece; 2Boehringer Ingelheim, Athens, Greece; 3University of Athens,
Athens, Greece; 4University of Athens, Athnes, Greece; 5University Hospital
Patras, Patras, Greece; 6Boehringer Ingelheim, Athens, Greece |
| PCV68 |
WITHDRAWN |
| PCV69 |
THE COST-EFFECTIVENESS OF
CYP2C9 GENOTYPING IN MANAGEMENT OF WARFARIN
THERAPY - A DECISION TREE ANAYSIS
You JH, Chan FW, Cheng G, The Chinese University of Hong Kong, Hong Kong,
China |
| PCV70 |
A PHARMACOECONOMIC COMPARISON OF UNFRACTIONATED HEPARIN AND LOW
MOLECULAR WEIGHT HEPARIN USAGE IN ACUTE CORONARY SYNDROME IN RUSSIA
Lazebnik LB1, Kuznetsova NA2, Gavrilova AV2, Komarova VP3, 1Russian State
Medical University, Moscow, Russia; 2Moscow Health Care Department, Moscow,
Russia; 3Aventis Pharma, Moscow, Russia |
| PCV71 |
AN ECONOMIC EVALUATION OF
TREATMENTS FOR ACUTE MI IN GREECE IN ELDERLY AND LATE TREATMENT PATIENTS
Maniadakis N1, Hatzikou M2, liappis T2, Kaitelidou D3, Spinthouri M4, Siskou
O3, Fragoulakis B5, Liaropoulos L4, 1University of Patras, Patras, Greece;
2Boehringer Ingelheim, Athens, Greece; 3University of Athens, Athens,
Greece; 4University of Athens, Athnes, Greece; 5University Hospital Patras,
Patras, Greece |
| PCV72 |
COST-EFFECTIVENESS OF ATORVASTATIN COMPARED TO SIMVASTATIN IN THE
NETHERLANDS
Severens JL1, Prins MH2, Monteban HC3, 1University Maastricht, Maastricht,
The Netherlands; 2University Hospital Maastricht, Maastricht, The
Netherlands; 3Pfizer, Capelle a/d IJssel, The Netherlands |
| |
|
| |
Cardiovascular Disease – Quality of Life Studies |
| PCV73 |
DEVELOPMENT OF
PATIENT-REPORTED OUTCOME MEASURES FOR PULMONARY ARTERIAL HYPERTENSION
McKenna SP1, Doughty N2, Pepke-Zaba J2, Meads D1, Doward L1, 1Galen
Research, Manchester, United Kingdom; 2Papworth Hospital, Cambridge, United
Kingdom |
| PCV74 |
MEASURING HEALTH
RELATED QUALITY OF LIFE AFTER STROKE
Lopez Bastida J1, Serrano Aguilar P1, Monton Alvarez F2, Duque González B1,
1Canarian Health Service, Santa Cruz de Tenerife, S/C de Tenerife, Spain;
2Ntra. Sra. de la Candelaria, Universitary Hospital, Santa Cruz de Tenerife,
S/C de Tenerife, Spain |
| PCV75 |
PROJECTED LIFE YEAR GAINED AND OTHER BENEFITS OF EZETIMIBE
CO-ADMINISTRATION IN CHD PATIENTS NOT ATTAINING TOTAL CHOLESTEROL GOAL WITH
STATIN MONOTHERAPY IN FINLAND
Cook J1, Alemao E2, Veltri E3, Yin DD4, 1Merck Research Labs, Blue Bell, PA,
USA; 2Merck and Co, Whitehouse Station, NJ, USA; 3Schering Plough
Pharmaceutical, Kenilworth, NJ, USA; 4Merck & Co., Inc, Whitehouse Station,
NJ, USA |
| PCV76 |
IS THE MLHF QUESTIONNAIRE VALID FOR INTERNATIONAL MULTICENTRIC
STUDIES?
Garin O1, Ferrer M1, Pont A1, Wiklund I2, Van Ganse E3, Pietri G3, Lobo-Luppi
L4, Alonso J1, 1Institut Municipal d'Investigació Mèdica, (IMIM-IMAS),
Barcelona, Cataluña, Spain; 2Astra Hässle Research Laboratoris, Möelndal,
Sweden; 3Lyon Sud Hospital, Lyon, France; 4for the IQOD group, Mapi Research
Institute, Lyon, France |
| PCV77 |
THE ECONOMIC ASSESSMENT OF
LIPID LOWERING THERAPY WITH EZETIMIBE IN
SPAIN
Davies GM1, Cook JR1, Nocea G2, Veltri E3, Alemao E4, Yin DD4, 1Merck
Research Labs, Blue Bell, PA, USA; 2Merck Sharp & Dohme, España, Madrid,
Spain; 3Schering Plough Pharmaceutical, Kenilworth, NJ, USA; 4Merck & Co.,
Inc, Whitehouse Station, NJ, USA |
| PCV78 |
QUALITY OF LIFE IN CHRONIC
PATHOLOGIES IN PRIMARY CARE
Leiva F1, Garcia Ruiz AJ2, Martos Crespo F2, Prados Torres JD1, Sanchez de
la Cuesta F2, 1Family Practice Department, Malaga, Spain; 2PharmacoEconomics
and Outcomes Research Unit, Malaga, Spain |
| PCV79 |
DEVELOPMENT AND VALIDATION
OF THE NEW HEALTH-RELATED QUALITY OF LIFE INSTRUMENT SPECIFIC TO
PATIENTS WITH CORONARY ARTERY DISEASE (CAD) IN POLAND: POL-CAD
Jaworski R1, Muszynska A2, Halik J3, Harmata W4, Czech M1, Pachocki R1,
1Servier Poland Research Institute, Warsaw, Poland; 2Medical University,
Warsaw, Poland; 3Centre for the Informative Systems in Health Care, Warsaw,
Poland; 4Military Institute of Chemistry and Radiometry, Warsaw, Poland |
| PCV80 |
EARLY EVOLUTION,
DETERMINANTS AND PREDICTIVE POWER OF HEALTH RELATED QUALITY OF LIFE IN A MULTICENTRIC POPULATION OF PATIENTS WITH HEART FAILURE
Permanyer-Miralda G, Soriano N,University Hospital Vall d'Hebron,
Barcelona, Spain |
| |
|
| |
|
DIABETES |
| |
Diabetes – Clinical Outcomes
Studies |
| PDB1 |
IMPROVED GLYCAEMIC CONTROL AND LESS HYPOGLYCAEMIA
WITH INSULIN GLARGINE COMPARED WITH NPH INSULIN IN PATIENTS WITH TYPE 2
DIABETES LEADS TO FEWER LONG-TERM COMPLICATIONS – RESULTS OF THE
DIABETES MELLITUS SIMULATION MODEL
Maxion-Bergemann S1, Müller E1, Bergemann R1, Walleser S1, Huppertz E2,
1Institute for Medical Outcome Research (IMOR) GmbH, Lörrach, Germany;
2Aventis Pharma Deutschland GmbH, Bad Soden/Taunus, Germany |
| PDB2 |
IS THERE A GAIN
WITH THE PAIN? ASSESSMENT OF THE RELATIONSHIP BETWEEN SELF-REPORTED
ADHERENCE TO SELF-MONITORING OF BLOOD GLUCOSE (SMBG) AND HBA1C LEVELS
AMONG TYPE 2 DIABETICS
Vincze G, Barner JC, Lopez DA, University of Texas at Austin, Austin,
TX, USA |
| PDB3 |
CLAIMS DATA
MEASUREMENTS OF MEDICATION ADHERENCE AND METABOLIC OUTCOMES IN PATIENTS
WITH TYPE 2 DIABETES (DM2)
Pladevall M, Loomis LA, Williams K, Xi H, Akkerman N, Elston-Lafata J,
Henry Ford Health System, Detroit, MI, USA |
| PDB4 |
POPULATION-BASED
DIABETES INTERVENTION IN A MANAGED CARE SETTING
Buchner DA1, Ershoff D2, Fazio C3, Mackey AL4, 1Schering-Plough,
Kenilworth, NJ, USA; 2Astra Zeneca, Tarzana, CA, USA; 3Medica,
Minnetonka, MN, USA; 4BMS, Eden Prairie, MN, USA |
| PDB5 |
EVIDENCE-BASED
ASSESSMENT OF PATIENTS' RISK AND POTENTIAL REGARDING THE LONG-TERM
COMPLICATIONS OF DIABETES USING A NEW MODEL OF PROGNOSIS IN THE DM
PROJECT DIAMART
Mast O1, Schumacher A2, Mueller A2, Lickvers K3, Kottmair S3, Derdzinski
BF4, Hecke T4, Ziegenhagen DJ4, Frank M5, 1Institute for Medical
Informatics and Biostatistics, Basel, Switzerland; 2HESTIA HealthCare
GmbH, Mannheim, Germany; 3ArztPartner almeda AG, Munich, Germany;
4Deutsche Krankenversicherung AG, Cologne, Germany; 5Saarlandklinik
Kreuznacher Diakonie, Neunkirchen, Germany |
| PDB6 |
PREVALENCE OF
RENAL FAILURE IN DIABETES TYPE 2: RESULTS FROM A POPULATION STUDY AND
THE BELGIAN ESRD REGISTRY
Verpooten GA, Nederlandstalige Belgische Vereniging voor Nefrologie,
Universiteit Antwerpen, Edegem, Belgium |
| PDB7 |
THE IMPACT ON
GLYCEMIC CONTROL OF DIABETIC PATIENTS BY A HOSPITAL PHARMACIST-MANAGED COMPLICANCE CLINIC IN HONG KONG
Lee VW, Leung PY, Lee KK, The Chinese University of Hong Kong, Shatin,
Hong Kong, China |
| PDB8 |
AN ANALYSIS OF
THE RELATIONSHIP BETWEEN RAPID TRANSITION TO INSULIN, AREA UNDER THE
CURVE FOR HBA1C MEASURES ACROSS TIME AND DIABETES-RELATED COMPLICATIONS:
A GERMANY POPULATION BASED STUDY
Simons WR1, Bolinder B2, Vinod H3, 1Global Health Economics & Outcomes
Research, Inc, Summit, NJ, USA; 2Aventis Pharmaceuticals, Bridgewater,
NJ, USA; 3Fordham University, Summit, NJ, USA |
| |
|
| |
Diabetes – Cost Studies |
| PDB9 |
THE
COMPACT-STUDY: PIOGLITAZONE VS. INSULIN FOR TREATMENT OF PATIENTS WITH
TYPE-2-DIABETES MELLITUS - A MEDICAL AND PHARMACOECONOMIC ANALYSIS
Lübben G1, Fennenkötter U1, Weidenhammer J2, Golbach U2, Kusterer K3,
Lundershausen R4, Münscher C5, Potthoff F5, 1TAKEDA PHARMA GMBH, Aachen,
Germany; 2Institut für Gesundheits- und Systemforschung GmbH, Kiel,
Germany; 3Diabetic Centre Mannheim, Mannheim, Germany; 4Clinic Bergfried
Saalfeld, Saalfeld, Germany; 5Medical NetCare GmbH, Münster, Germany |
| PDB10 |
DIABETES
DISEASE MANAGEMENT IS ASSOCIATED WITH PHARMACY SAVINGS IN A MANAGED CARE
SETTING
Sidorov J1, Wolke OF2, Fischer FJ3, 1Geisinger Health Plan, Danville,
PA, USA; 2Schellen and Partners Usa, Inc., Danville, PA, USA; 3Schellen
and Partner GmbH, Düsseldorf, Germany |
| PDB11 |
THE ECONOMIC
CONSEQUENCES OF DIABETES TYPE 2 IN POLAND
Niewada MP1, Glogowski CA2, Pietrasik AL1, £atek M3, Kamiñski B3,
Gierczynski JM2, Krzyzanowska AM2, 1Medical University of Warsaw,
Warsaw, Poland; 2GlaxoSmithKline Pharmaceuticals S.A, Warsaw, Poland;
3Warsaw School of Economics, Warsaw, Poland |
| PDB12 |
TYPE-2 DIABETES
AND HOSPITAL COSTS ACCORDING TO OBESITY: A RETROSPECTIVE ANALYSIS FROM A
HOSPITAL DATA BASE IN FRANCE
Riveline JP1, Petit C1, Dinet J2, Sevellec C3, Nabarette H3, Dispot T3,
Charpentier G1, 1Centre Hospitalier Sud Francilien, Corbeil-Essonnes,
France; 2Sanofi-Synthelabo Recherche, Bagneux, France; 3Medcost, Paris,
France |
| PDB13 |
PREDICTORS OF
EMERGENCY DEPARTMENT VISITS IN ELDERLY PATIENTS WITH DIABETES
Chen GJ, Teuschler H, Moran WP, Wake Forest University Health Science,
Winston-Salem, NC, USA |
| PDB14 |
COST-
EFFECTIVENESS ANALYSIS OF THE ACARBOSE PHARMACOLOGICAL TREATMENT AS A
PREVENTIVE MEASURE OF THE DEVELOPMENT OF TYPE 2 DIABETES IN SUBJECTS
DIAGNOSED OF IMPAIRED GLUCOSE TOLERANCE (IGT)
Sabés R, Universitat Pompeu Fabra, Barcelona, Spain |
| |
|
| PDB15 |
RISK OF
CONGESTIVE HEART FAILURE IN TYPE 2 DIABETICS EXPOSED TO PIOGLITAZONE VS
INSULIN: A MATCHED COHORT ANALYSIS
Rajagopalan R1, Rosenson R2, Murray FT1, 1Takeda Pharmaceuticals North
America, Inc, Lincolnshire, IL, USA; 2Northwestern University, Feinberg
School of Medicine, Chicago, IL, USA |
| PDB16 |
COST-EFFECTIVENESS OF BLOOD PRESSURE AND URINARY ALBUMIN CONTROL IN
DIABETICS WITH AN ANGIOTENSIN II RECEPTOR ANTAGONIST AND A CALCIUM
CHANNEL BLOCKER: PHARMACOECONOMIC ANALYSIS OF THE MARVAL TRIAL – THE
CASE OF GERMANY
Smith DG1, Gnanasakthy A2, Quednau K3, 1University of Michigan, Ann
Arbor, MI, USA; 2Novartis Pharmaceuticals Corporation, East Hanover, NJ,
USA; 3Novartis Pharma GmbH, Nuremberg, Germany |
| PDB17 |
PREDICTED COSTS
AND OUTCOMES FROM REDUCED VIBRATION DETECTION IN PEOPLE WITH DIABETES IN
THE UK
Shearer A1, Scuffham P1, Gordois A1, Oglesby A2, 1University of York,
York, United Kingdom; 2Eli Lilly & Company, Indianapolis, IN, USA |
| PDB18 |
THE
COMPLICATIONS IMPACT ON DIABETES TYPE 2 DIRECT COSTS IN POLAND
Niewada MP1, Glogowski CA2, Latek M3, Pietrasik A3, Kamiñski B3,
Gierczynski JM2, Krzy¿anowska A2, 1Medical University of Warsaw, Warsaw,
Poland; 2GlaxoSmithKline Pharmaceuticals S.A, Warsaw, Poland; 3Warsaw
School of Economics, Warsaw, Poland |
| PDB19 |
ADVANCED TOOLS
FOR ALLOCATION OF MEDICAL PRODUCTS: ECONOMIC EVALUATION OF THE
"HOMECARE" PROGRAMME
de Portu S1, Gradnik PA2, Recchia A2, Munna E2, Mantovani LG3,
1University of Milan, Milan, Italy; 2Associazione Chimica Farmaceutica
LOMBARDA fra Titolari di Farmacia, Milan, Italy; 3University of Milan,
Milan, Italy |
| PDB21 |
A COST-UTILITY
ANALYSIS OF INSULIN GLARGINE (LANTUS®) IN THE TREATMENT OF PATIENTS WITH
TYPE 1 DIABETES
Kristensen FK1, Sverre JM1, Bustad S2, 1PharmEcon AS, Asker, Norway;
2Aventis Pharma AS, Lysaker, Norway |
| |
|
| |
Diabetes
– Quality of Life Studies |
| PDB20 |
THE IMPACT
OF DIABETES TYPE 2 ON QUALITY OF LIFE
Niewada MP1, Glogowski CA2, Gierczynski JM2, Latek M3, Pietrasik AL1,
Kamiñski B3, Krzyzanowska AM2, 1Medical University of Warsaw, Warsaw,
Poland; 2GlaxoSmithKline Pharmaceuticals S.A, Warsaw, Poland; 3Warsaw
School of Economics, Warsaw, Poland |
| |
|
GASTROINTESTINAL DISEASES/DISORDERS |
| |
Gastrointestinal Disorders –
Clinical Outcomes Studies |
| PGS1 |
AN
EVIDENCE-BASED APPROACH PROVIDES A QUANTITATIVE ASSESSMENT OF THE
EFFICACY OF ESOMEPRAZOLE FOR HEALING OF EROSIVE ESOPHAGITIS BASED ON
DISEASE SEVERITY
Johnson DA1, Roach A2, Traxler BM2, Levine D2, 1Eastern Virginia School
of Medicine, Norfolk, VA, USA; 2AstraZeneca LP, Wilmington, DE, USA |
| PGS2 |
A RETROSPECTIVE
AUDIT OF PATIENTS REDUCING PROTON PUMP INHIBITOR DOSE TO LANSOPRAZOLE
15MG
Emmas CE, Rosen JP, AstraZeneca UK, Luton, United Kingdom |
| PGS3 |
META-ANALYSIS OF
PPI-BASED TRIPLE THERAPY FOR THE ERADICATION OF HELICOBACTER PYLORI
Edwards SJ, Plumb JM, AstraZeneca UK Ltd, Luton, Bedfordshire, United
Kingdom |
| PGS4 |
ESOMEPRAZOLE AS
MAINTENANCE THERAPY IN EROSIVE ESOPHAGITIS: A QUANTITATIVE ASSESSMENT OF
EFFICACY USING AN EVIDENCE-BASED APPROACH
Johnson DA1, Roach A2, Traxler BM2, Levine D2, Lauritsen K3, 1Eastern
Virginia School of Medicine, Norfolk, VA, USA; 2AstraZeneca LP,
Wilmington, DE, USA; 3Odense University Hospital, Odense, Denmark |
| |
|
| |
Gastrointestinal Disorders –
Cost Studies |
| PGS5 |
ECONOMIC BURDEN
OF IRRITABLE BOWEL SYNDROME (IBS): ONE YEAR RESULTS. RITMO STUDY
Badia X1, Mearín F2, Caballero A3, Benavent J4, Díaz-Rubio M5, Domínguez
E6, Garrigues V7, Vázquez J8, Piqué J9, Figueres M10, Cucala M10, Balañá
M10, Roset M1, RITMO Study Group11, 1Health Outcomes Research Europe,
Barcelona, Spain; 2Centro Médico Teknon, Barcelona, Spain; 3Granada
University. School of Medicine, Granada, Spain; 4Área Básica de Salud de
Montigalá, Badalona, Spain; 5Hospital Clínico San Carlos, Madrid, Spain;
6Hospital Clínico Universitario de Galícia, Santiago de Compostela,
Spain; 7Hospital de la Fe, Valencia, Spain; 8Clínica del aparato
digestivo, A Coruña, Spain; 9Hospital Clínico de Barcelona, Barcelona,
Spain; 10Novartis Farmacéutica, Barcelona, Spain; 11Barcelona, Spain |
| PGS6 |
COST
EFFECTIVENESS OF CONTINUOUS AND ON-DEMAND THERAPY WITH ESOMEPRAZOLE 20
MG IN PATIENTS WITH SYMPTOMATIC GASTROESOPHGEAL REFLUX DISEASE (GERD):
THE ONE STUDY
Edouard L1, Urbain D2, Vandenhoven G3, Duquenne V3, 1University Hospital
of Liege, Liege, Belgium; 2Free University of Brussels, Jette, Belgium;
3AstraZeneca, Bruxelles, Belgium |
| PGS7 |
COST ANALYSIS OF
A NEW PROPOSAL FOR REIMBURSEMENT OF PROTON PUMP INHIBITOR TREATMENT
OF GASTROESOPHAGEAL REFLUX DISEASE (GERD) IN BELGIUM
Van Wilder PB1, Arickx F1, Vannecke C1, Hiele M2, Verpooten GA3,
1RIZIV-INAMI, Brussels, Belgium; 2KU Leuven, Leuven, Belgium;
3University of Antwerpen, Edegem, Belgium |
| PGS8 |
COST-MINIMISATION
ANALYSIS OF PPI-BASED TRIPLE THERAPY FOR THE ERADICATION OF HELICOBACTER
PYLORI
Plumb JM, Edwards SJ, AstraZeneca UK Ltd, Luton, Bedfordshire, United
Kingdom |
| PGS9 |
A COST
CONSEQUENCE ANALYSIS OF A NEW ENDOSCOPIC INJECTABLE TREATMENT VERSUS
SURGERY IN PATIENTS WITH SEVERE GASTRO ESOPHAGEAL REFLUX DISEASE IN
FRANCE
Lamarsalle L1, Castanier J1, Vainchtock A1, Granger-Pascot M2, 1GYD
Institut, Lyon, France; 2Boston Scientific France, St Quentin en
Yvelines, France |
| PGS10 |
COST OF ILLNESS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD) IN ITALY
Di Stasi F1, Teruzzi C2, Mantovani LG1, 1University of Milan, Milan, Italy;
2Bracco, Milan, Italy |
| PGS11 |
USING A
COST-UTILITY ANALYSIS FOR ASSESSING SENSITIVITY IN DRUG PRICES OF ESOMEPRAZOLE VERSUS OMEPRAZOLE IN THE ACUTE TREATMENT OF REFLUX
OESOPHAGITIS IN THE UK
Wahlqvist P, AstraZeneca R&D Mölndal, Mölndal, Sweden |
| PGS12 |
IMPACT ON WORK
PRODUCTIVITY OF UPPER GASTROINTESTINAL SYMPTOMS ASSOCIATED WITH CHRONIC NSAID THERAPY IN A SWEDISH STUDY POPULATION
Wahlqvist P, Bergenheim K, Långström G, Naesdal J, AstraZeneca R&D Mölndal,
Mölndal, Sweden |
| PGS13 |
COST OF ILLNESS
AND QUALITY OF LIFE OF GASTROESOPHAGEAL REFLUX DISEASE
(GERD) PATIENTS IN ITALY
Rossetti F, Montovani L, University of Milan, Milan, Italy |
| PGS14 |
CROHN´S DISEASE IN SLOVAKIA AND QUALITY OF LIFE
Bielik J, Hlista M, Èernok S, Šorf M
Hospital Nové Mesto nad Váhom, Hospital Trenèín, Slovakia, Slovak
Republic |
| |
|
| |
|
MENTAL HEALTH |
| |
Mental Health – Clinical Outcomes Studies |
| PMH1 |
METHYLPHENIDATE
FORMULATION IS ASSOCIATED WITH ACCIDENT/INJURY RATE IN CHILDREN WITH
ADHD
Lage M1, Hwang P2, 1HealthMetrics Outcomes Research, Groton, CT, USA;
2Janssen-Ortho Inc, Toronto, ON, Canada |
| PMH2 |
EVALUATION OF
ANTIDEPRESSANT MEDICATION ADHERENCE IN A NOT FOR PROFIT HEALTH CARE
ORGANIZATION
Alison LM1, Wong SL2, Day D3, 1Healthfirst, Inc, New York, NY, USA; 2Pfizer,
Inc, Syosset, NY, USA; 3Pfizer, Inc, New York, NY, USA |
| PMH3 |
EVALUATION OF MEDICAL DIAGNOSES FOR TEXAS MEDICAID PATIENTS PRESCRIBED
ATYPICAL ANTIPSYCHOTIC MEDICATIONS
Harrington PM1, Rascati KL1, Johnsrud M2, 1The University of Texas College
of Pharmacy, Austin, TX, USA; 2The Center for Pharmacoeconomic Studies - The
University of Texas, Austin, TX, USA |
| PMH4 |
2-YEAR OUTCOMES
OF RISPERDAL® CONSTA™ - THE FIRST ATYPICAL LONG ACTING
INJECTABLE ANTIPSYCHOTIC: RESULTS FROM THE CANADIAN NATIONAL OUTCOMES
MEASUREMENT STUDY IN SCHIZOPHRENIA
Trakas K1, Talling D2, Balshaw R2, Love L2, Robinson K1, 1Janssen-Ortho Inc,
Toronto, ON, Canada; 2Syreon Corporation, Vancouver, BC, Canada |
| PMH5 |
FUNCTIONING AND
HEALTH CARE RESOURCE USE OF SCHIZOPHRENIC PATIENTS IN A ONE-YEAR
FOLLOW-UP STUDY. SOHO STUDY
Prieto L1, Escobar R1, Bousoño M2, González-Torres M3, Mayoral F4, Montejo
A5, Olivares J6, Ros S7, Sanjuan J8, 1Lilly, S.A, Alcobendas, Madrid, Spain;
2Universidad de Oviedo, Alcobendas, Madrid, Spain; 3Hospital de Basurto,
Bilbao, Vizkaia, Spain; 4Complejo Hospitalario Carlos Haya, Málaga, Spain;
5Hospital Universitario de Salamanca, Salamanca, Spain; 6Complejo
Hospitalario Xeral-Cies, Vigo, Pontevedra, Spain; 7Hospital del Mar,
Barcelona, Spain; 8Universidad de Valencia, Alcobendas, Madrid, Spain |
| PMH6 |
PHARMACOUTILIZATION OF ANTIDEPRESSANT DRUGS IN PRIMARY CARE: A
LONG-TERM RETROSPECTIVE ANALYSIS OF A LARGE POPULATION
Russo P1, Degli Esposti L2, Baiardi F2, Degli Esposti E3, Carmosino G4,
1University of Rome "La Sapienza", Rome, Italy; 2CliCon Srl, Health
Economics and Outcomes Research, Ravenna, Italy; 3Ravenna Local Health Unit,
Ravenna, Italy; 4Lundbeck Italy, Milan, Italy |
| |
|
| |
Mental Health – Cost Studies |
| PMH7 |
COST
EFFECTIVENESS OF PHARMACOLOGICAL TREATMENT VERSUS CARE AS USUAL FOR
PANIC DISORDER AND/OR DEPRESSION DRIVEN CHEST PAIN: PRELIMINARY RESULTS
OF UNBLINDED DATA
Brunenberg D, Dirksen C, Kuijpers P, Honig A, University Hospital
Maastricht, Maastricht, The Netherlands |
| PMH8 |
PREVALENCE
AND MEDICAL CARE COSTS OF ANXIETY DISORDERS IN THE UNITED STATES: A
NATIONAL ESTIMATE USING THE MEDICAL EXPENDITURE PANEL SURVEY
Mychaskiw MA, Sankaranarayanan J, Purdue University, West Lafayette, IN, USA |
| PMH9 |
THE
SOCIO-ECONOMIC BURDEN OF BIPOLAR DISORDER IN THE NETHERLANDS
Hakkaart L1, Hoeijenbos M1, Regeer EJ2, ten Have M3, Nolen WA4, Veraart C5,
Rutten F6, 1Erasmus University Rotterdam, Rotterdam, The Netherlands;
2Altrecht Institute for Mental Health Care, Utrecht, The Netherlands; 3The
Netherlands Institute for Mental Health and Addiction, Utrecht, The
Netherlands; 4Altrecht Institute for Mental Health Care, Utrecht, The
Netherlands; 5Eli Lilly, The Netherlands, Houten, Utrecht, The Netherlands;
6Institute for Medical Technology Assessment, Erasmus Medical Centre, The
Netherlands, Rotterdam, Zuid-Holland, The Netherlands |
| PMH10 |
COSTS AND
EFFECTS OF RISPERDAL CONSTATM IN COMPARISON TO CONVENTIONAL
DEPOT AND SHORT-ACTING ATYPICAL FORMULATIONS IN GERMANY
Heeg BM1, Emmermann A2, Laux G3, Möller HJ4, Naber D5, Van Hout BA1,
1PharMerit BV, Capelle a/d IJssel, The Netherlands; 2Janssen-Cilag GmbH,
Neuss, Germany; 3Bezirkskrankenhaus Gabersee, Wasserburg, Germany; 4Klinikum
der Universität München, München, Germany; 5Universitätskrankenhaus
Eppendorf, Hamburg, Germany |
| PMH11 |
PRODUCTION
LOSSES IN BORDERLINE PERSONALITY DISORDER: SHORTCOMINGS IN THE STANDARD
METHODS OF VALUATION
van Asselt ADI1, Dirksen CD1, Severens JL2, Arntz A2, 1University Hospital
Maastricht, Maastricht, The Netherlands; 2University Maastricht, Maastricht,
The Netherlands |
| |
|
| PMH12 |
ECONOMIC
CONSEQUENCES OF THE ADVERSE EVENTS RELATED WITH CURRENT ANTIPSYCHOTICS
Bobes J1, Cañas F2, Rejas J3, Expósito I4, Mackell JA5, 1University of
Oviedo, Oviedo, Spain; 2Psyquiatric Hospital of Madrid, Madrid, Spain;
3Health Outcomes Research, Medical Unit, Pfizer SA, Alcobendas, Madrid,
Spain; 4Health Outcomes Research, Pfizer SA, Alcobendas, Madrid, Spain;
5Pfizer Inc, New York, NY, USA |
| PMH13 |
AFFECTIVE
PSYCHOSES IN ADOLESCENTS: THE ECONOMIC CONSEQUENCES OF ACUTE CARE
HOSPITAL ADMISSIONS OVER THREE YEARS
O'Brien JA, Pitoniak-Morse CA, Caro JJ, Caro Research Institute, Concord,
MA, USA |
| PMH14 |
THE BURDEN OF
ATTENTION DEFICIT AND HYPERACTIVITY DISORDER (ADHD) IN THE NORDIC
COUNTRIES - A LITERATURE REVIEW
Närhi V1, Bernfort L2, Heikkinen K3, Myrén K4, 1Niilo Mäki Institute,
Jyväskylä, Finland; 2Center for Medical Technology Assessment (CMT),
Linköping, Sweden; 3Oy Eli Lilly Finland AB, Vantaa, Finland; 4Eli Lilly
Sweden AB, Stockholm, Sweden |
PMH15
|
COST-EFFECTIVENESS ANALYSIS OF LONG-ACTING RISPERIDONE (LA-RIS) VS
HALOPERIDOL DECANOATE AND ORAL OLANZAPINE IN THE TREATMENT OF SCHIZOPHRENIA
IN ITALY
D'Ausilio A1, Amaddeo F2, Mencacci C3, Munizza C4, Miadi-Fargier H5, Berto
P1, 1PBE consulting, Verona, Italy; 2Ospedale Policlinico "G.B. Rossi",
Verona, Italy; 3Azienda Ospedaliera Fatebenefratelli-Oftalmico, Milano,
Italy; 4ASL, Torino, Italy; 5A.C.E. Annie Chicoye Economics,
Neuilly-sur-Seine, France |
| PMH16 |
AN ECONOMIC
EVALUATION OF ARIPIPRAZOLE VERSUS OLANZAPINE IN A SWEDISH
SETTING USING OUTCOMES OF METABOLIC SYNDROME, PROJECTED DIABETES AND
CORONARY HEART DISEASE
Ruppert A1, Waldeck R2, Cislo P2, Pugner K1, Iwamoto T3, Yuan Y4, Ösby U5,
1Bristol-Myers Squibb, Waterloo, Belgium; 2Bristol-Myers Squibb,
Wallingford, CT, USA; 3Bristol Myers Squibb, Wallingford, CT, USA; 3Otsuka,
Rockville, MD, USA; 4Bristol-Myers Squibb, Princeton, NJ, USA; 5 Karolinska
Institute, Stockholm, Sweden |
| |
|
| |
Mental Health – Quality of Life Studies |
| PMH17 |
HEALTH-RELATED
QUALITY OF LIFE IN OUTPATIENTS WITH SCHIZOPHRENIA IN SINGAPORE
Luo N1, Seng BK2, Li SC1, Thumboo J3, 1National University of Singapore,
Singapore; 2Institute of Mental Health, Singapore, Singapore; 3Singapore
General Hospital, Singapore, Singapore |
| PMH18 |
ZIPRASIDONE VS OLANZAPINE: CHANGE IN CHD RISK DURING A SIX-WEEK TRIAL
Mackell JA, Leaderer MC, Pfizer Pharmaceuticals Group, Pfizer, Inc, New
York, NY, USA |
| PMH19 |
CLIENT AND STAFF
INVOLVEMENT IN FORMAT DESIGN OF A HEALTH-RELATED QUALITY OF LIFE SURVEY
FOR INDIVIDUALS WITH SCHIZOPHRENIA, THE SCHIZOPHRENIA OUTCOMES
ASSESSMENT PROJECT (SOAP) SURVEY
Barr JT, Schumacher GE, Ohman SM, Quimby CM, Northeastern University,
Boston, MA, USA |
| PMH20 |
TREATMENT WITH PSYCHOSTIMULANTS IS ASSOCIATED WITH DECREASED RATES OF
SUBSTANCE ABUSE AND IMPROVED SCHOOL OUTCOMES AMONG CHILDREN WITH AD/HD
Katusic SK, Barbaresi WJ, Colligan RC, Weaver AL, Mrazek DA, Jacobsen SJ,
Mayo Clinic, Rochester, MN, USA |
| PMH21 |
PSORIASIS AND
DEPRESSIVE SYMPTOMATOLOGY: SPANISH RESULTS
Taïeb C1, Garrido JA2, Myon E1, 1Pharmaco Economics & Quality of Life
Department, Boulogne Billancourt, France; 2Pierre Fabre Iberica, Barcelona,
Spain |
| PMH22 |
PSORIASIS AND
DEPRESSIVE SYMPTOMATOLOGY: ITALIAN RESULTS
Taïeb C1, Garrido JA2, Myon E1, 1Pharmaco Economics & Quality of Life
Department, Boulogne Billancourt, France; 2Pierre Fabre Iberica, Barcelona,
Spain |
| |
|
| PMH24 |
EARLY SUSTAINED
REMISSION IN PATIENT-REPORTED OUTCOMES AMONG PRIMARY CARE PATIENTS WITH
MAJOR DEPRESSIVE DISORDER
Sapin C1, Fantino B2, François C3, 1Altipharm, Paris, France;
2ADIM-AGORAS, Lyon, France; 3H. Lundbeck A/S, Paris, France |
| PMH25 |
ASSESSING
HEALTH-RELATED QUALITY OF LIFE IN CLINICAL TRIALS OF PATIENTS WITH MAJOR
DEPRESSIVE DISORDER
Sapin C1, Le Lay A2, Llorca PM3, François C2, 1Altipharm, Paris, France; 2H.
Lundbeck A/S, Paris, France; 3CH Sainte-Marie, Clermont-Ferrand, France |
| PMH26 |
QUALITY OF LIFE
IN SCHIZOPHRENIC PATIENTS IN SPAIN: ONE-YEAR FOLLOW-UP STUDY. SOHO STUDY
Prieto L1, Escobar R1, Bousoño M2, González-Torres M3, Mayoral F4, Montejo
A5, Olivares J6, Ros S7, Sanjuan J8, 1Lilly, S.A, Alcobendas, Madrid, Spain;
2Universidad de Oviedo, Alcobendas, Madrid, Spain; 3Hospital de Basurto,
Bilbao, Vizkaia, Spain; 4Complejo Hospitalario Carlos Haya, Málaga, Spain;
5Hospital Universitario de Salamanca, Salamanca, Spain; 6Complejo
Hospitalario Xeral-Cies, Vigo, Pontevedra, Spain; 7Hospital del Mar,
Barcelona, Spain; 8Universidad de Valencia, Alcobendas, Madrid, Spain |
| |
|
| |
|
|
URINARY/KIDNEY DISEASES OR DISORDERS |
| |
Urinary/Kidney Diseases or Disorders – Clinical Outcomes Studies |
| PUK1 |
THE USE OF A
URINARY CATHETER REMINDER TO REDUCE URINARY CATHETERIZATION IN
HOSPITALIZED PATIENTS
Saint S1, Kaufman S2, Thompson M2, Rogers M2, Chenoweth C2, 1Ann Arbor VA
Medical Center and University of Michigan Medical School, Ann Arbor, MI,
USA; 2University of Michigan, Ann Arbor, MI, USA |
| PUK2 |
TREATMENT
PERSISTENCE OF OXYBUTYNIN XL AND TOLTERODINE IR IN A
REAL-WORLD CLINICAL PRACTICE SETTING: DATA FROM THE UNITED KINGDOM
Feng W1, Dubois D2, Neslusan C1, Simons WR3, 1Johonson & Johnson
Pharmaceutical Services, L.L.C, Raritan, NJ, USA; 2Johnson & Johnson
Pharmaceutical Services, LLC, Beerse, Belgium; 3Global Health Economics &
Outcomes Research, Inc, Summit, NJ, USA |
| PUK3 |
TREATMENTS
RECEIVED FOR STRESS URINARY INCONTINENCE (SUI) SYMPTOMS BY
PATIENTS SEEKING HELP WITHIN A UK PRIMARY CARE SETTING
Martin ML1, Bushnell DM1, Das Gupta RJ2, Assassa P3, Shaw C4, 1Health
Research Associates, Inc, Mountlake Terrace, WA, USA; 2Eli Lilly UK,
Basingstoke, Hampshire, United Kingdom; 3Mid Yorkshire Trust, Pontefract,
United Kingdom; 4Chris Shaw, Newport Gwent, S Wales, United Kingdom |
| PUK4 |
TREATMENT OF
URINARY INCONTINENCE IN DAILY PRACTICE DOES NOT COMPLY WITH THE
GUIDELINES
Penning-van Beest FJA1, Sturkenboom MCJM2, Herings RMC1, 1PHARMO Institute,
Utrecht, The Netherlands; 2Erasmus MC, Rotterdam, The Netherlands |
| |
|
| |
Urinary/Kidney Diseases or Disorders - Cost Studies |
| PUK5 |
COMPARISON
OF THE DOSE AND COST OF EPREX BY ROUTE OF ADMINISTRATION
Trakas K, Robinson K, Janssen-Ortho Inc, Toronto, ON, Canada |
| PUK6 |
COST-MINIMIZATION ANALYSIS OF TENSION-FREE VAGINAL TAPE VS. OPEN BURCH COLPOSUSPENSION IN FEMALE STRESS URINARY INCONTINENCE
Lahoz R1, Magaz S2, Badia X2, Amat L3, Bielsa O4, Díez-Gómez E5, Fillol M6,
Gálmes Í7, Santiago A8, Santisteban J9, 1Health Outcomes Policy And
Economics, Barcelona, Spain; 2Health Outcomes Research Europe, Barcelona,
Spain; 3Hospital Sant Joan De Deu, Barcelona, Spain; 4Hospital Nuestra
Señora Del Mar, Barcelona, Spain; 5Hospital General Universitario Gregorio
Marañón, Madrid, Spain; 6Hospital Vila-Real, Castellón, Spain; 7Hospital
Universitario Santa Cristina, Madrid, Spain; 8Hospital Virgen Del Camino,
Navarra, Spain; 9Hospital Universitario La Paz, Madrid, Spain |
| PUK7 |
DITROPAN XL VERSUS DETROL IN CANADA: ECONOMIC ANALYSIS
Getsios D1, Caro J2, Ishak K3, El-Hadi W3, Payne KA4, Luong D5, McMahon D6,
1Caro Research Institute, Halifax, NS, Canada; 2Caro Research Institute,
Concord, MA, USA; 3Caro Research Institute, Dorval, QC, Canada; 4Caro
Research Institute, Montreal, QC, Canada; 5Janssen Ortho Inc, Toronto, ON,
Canada; 6Confex, Cumberland, RI, USA |
| PUK8 |
SEVELAMER USE IN HYPERPHOSPHATEMIA: HEALTH AND ECONOMIC CONSEQUENC | | |
